MAP2

Across TCGA pan-cancer cohorts, MAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where MAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.460	0.293	.007	31	view →
LUAD	DFS	Tertile	All	0.850	0.958	.001	19	view →
HNSC	DFS	Median	II,III,IV	0.976	0.895	.030	9	view →
GBM	DFS	Quartile	All	0.900	0.656	.007	8	view →
LSCC	OS	Quartile	III,IV	0.905	0.500	.039	4	view →
CCRCC	DFS	Tertile	III,IV	0.802	0.455	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP2–PDAC (OS)

Open the PDAC breakdown →